Table of contents

  • Summary
  • 1. Introduction
    • 1.1 Purpose of this report
    • 1.2 Pharmaceutical Benefits Scheme
    • 1.3 Management of musculoskeletal conditions
    • 1.4 Data source—Pharmaceutical Benefits Scheme
    • 1.5 Analysis methods
    • 1.6 Data limitations and information gaps
  • 2. Results
    • 2.1 Medication use for ankylosing spondylitis
    • 2.2 Medication use for psoriatic arthritis
    • 2.3 Medication use for juvenile arthritis
  • 3. Discussion
    • 3.1 Key findings
    • 3.2 Future work
  • Appendix A: Medications analysed
  • Appendix B: Data tables
  • Acknowledgments
  • Abbreviations
  • References
  • List of tables
  • List of figures
Next page